Edition:
India

OHR Pharmaceutical Inc (OHRP.OQ)

OHRP.OQ on NASDAQ Stock Exchange Capital Market

0.26USD
21 Feb 2018
Change (% chg)

-- (--)
Prev Close
$0.26
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
435,358
52-wk High
$2.17
52-wk Low
$0.24

Latest Key Developments (Source: Significant Developments)

Ohr Pharmaceutical Announces Efficacy Results From The Mako Study In Wet-Amd
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Ohr Pharmaceutical Inc ::OHR PHARMACEUTICAL ANNOUNCES EFFICACY RESULTS FROM THE MAKO STUDY IN WET-AMD.OHR PHARMACEUTICAL INC - ‍TOPLINE DATA FROM MAKO STUDY DID NOT MEET ITS PRIMARY EFFICACY ENDPOINT​.OHR PHARMACEUTICAL INC - "WE ARE VERY DISAPPOINTED WITH OUTCOME OF MAKO STUDY".OHR PHARMACEUTICAL INC - ‍INTEND TO EVALUATE STRATEGIC ALTERNATIVES TO "MAXIMIZE SHAREHOLDER VALUE"​.OHR PHARMA - SUBJECTS RECEIVING SQUALAMINE COMBINATION THERAPY ACHIEVED MEAN GAIN OF 8.33 LETTERS FROM BASELINE VERSUS 10.58 FROM LUCENTIS MONOTHERAPY.  Full Article

OHR Pharmaceutical Reports Fiscal Year 2017 Financial Results
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Ohr Pharmaceutical Inc ::OHR PHARMACEUTICAL REPORTS FISCAL YEAR 2017 FINANCIAL RESULTS.OHR PHARMACEUTICAL INC - REMAIN ON TRACK TO RECEIVE AND REPORT TOP-LINE EFFICACY DATA FROM MAKO STUDY IN EARLY CALENDAR 2018.  Full Article

OHR Pharmaceutical Q2 loss per share $0.17
Wednesday, 11 May 2016 

Ohr Pharmaceutical Inc : OHR Pharmaceutical Inc says for q2 ended march 31, 2016, total operating expenses were approximately $6.6 million . OHR Pharmaceutical reports second quarter 2016 financial and business results .Q2 loss per share $0.17.  Full Article

BRIEF-Ohr Pharmaceutical Q1 Loss Per Share $0.07

* OHR PHARMACEUTICAL REPORTS FISCAL FIRST QUARTER 2018 FINANCIAL RESULTS